“It’s actually baricitinib that’s the generic name, but it has a brand name: Olumiant,” he said during the Sept. 7 episode of “The Dr. Ardis Show” on Brighteon.TV.
“This drug Olumiant – the reason why it came to my attention was the hospital pharmacist. The first one said that it has four black box warnings of how it’s proven, in research studies, to kill people. The truth is, it actually has five.”
According to Ardis, the Food and Drug Administration (FDA) approved baricitinib as a COVID-19 treatment for adults in May 2022. However, it remained under emergency use authorization (EUA) for treating COVID-19 in children aged two to 18. Ardis pointed to a document from the FDA itself admitting there is no pediatric data to support baricitinib as a COVID-19 treatment for younger patients. (Related: FDA grants full approval to untested Pfizer COVID-19 vaccine for adolescents.)
Baricitinib, which is manufactured by Eli Lilly, was originally granted an EUA in November 2020 in combination with remdesivir. This EUA was later revised in July 2021 to reflect its approval as a standalone COVID-19 treatment.
“There is no data to show it is safe and effective or not dangerous,” explained Ardis. “It’s on the document so they have not researched this.”
He continued that one of the five black box warnings advised against prescribing the drug to someone with a serious infection, especially a localized one.
Ardis’ guest Priscilla Romans, the founder and CEO of patient advocacy company Graith Care, agreed with him. She added that the warning was one of the reasons why they inform their patients about the drug.
According to Romans, the medication has been listed on one of the informed documents that they provide people since last year. Even though the fact sheet clearly warned against giving baricitinib to a patient with a localized or serious infection, the FDA still approved it.
Ardis: Baricitinib increases the possibility of developing blood clots
Ardis, a chiropractor, mentioned that baricitinib is known to increase the risk of a person dying from blood clots called thrombosis, including deep vein thrombosis and pulmonary embolism. Romans added that some of these blood clots are so deadly that the patient usually does not survive.
Aside from increasing the severity of a serious infection that can be lethal, Ardis said baricitinib increases the fatality of a heart attack. It also increases the chance of developing blood clots in the lungs, veins and arteries, alongside cardiovascular events such as strokes, aneurysms, myocarditis and myocardial infarction. Moreover, baricitnib increases metastatic cancers and lymphadenopathy in the body.
He recounted a conference in St. Louis where he served as a guest speaker. When he made the revelation about baricitinib, the medical doctors who attended were all shocked to learn about its authorization for children aged two to 18 despite its fatal side effects.
Romans stressed that patients need to understand that they have the right to refuse a drug. She also remarked that when people take a medication, they need to make sure that the prescription is correct and they are following the recommended guidelines for the medicine.
Follow DangerousMedicine.com for more news about the deadly drugs approved and used for COVID treatment.
More related articles: